Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.83 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812425 | 0.91 | MAPK14 (1.00) | MAPK14HSPB1 | |
| SCHEMBL4701717 | 0.89 | MAPK14 (0.75) | MAPK14HSPB1RAF1LYN | |
| SCHEMBL4701715 | 0.88 | MAPK14 (0.72) | MAPK14HSPB1RAF1LYN | |
| SCHEMBL4705471 | 0.84 | MAPK14 (0.83) | MAPK14HSPB1RAF1LYN | |
| SCHEMBL4815165 | 0.80 | MAPK14 (1.00) | MAPK14HSPB1 | |
| SCHEMBL4820863 | 0.79 | MAPK14 (0.74) | MAPK14HSPB1 | |
| SCHEMBL4819879 | 0.79 | MAPK14 (1.00) | MAPK14HSPB1 | |
| SCHEMBL4702294 | 0.79 | MAPK14 (0.68) | MAPK14HSPB1 | |
| SCHEMBL5102820 | 0.78 | MAPK14 (0.80) | MAPK14HSPB1 | |
| SCHEMBL3402871 | 0.78 | MAPK14 (0.75) | MAPK14HSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436272-B1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-05-07 | — | — | EP | claimed |
| US-7309800-B2 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-12-18 | — | — | US | claimed |
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-10 | — | — | US | claimed |
| US-7151118-B2 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-12-19 | — | — | US | claimed |
| EP-1436272-B1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-7309800-B2 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-7151118-B2 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-12-19 | — | — | US | disclosed |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK3 | MAPK14 6/4885HSPB1 744/4885RAF1 67/4885 |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | MAPK1, MAPKAPK2, MAP3K1 | MAPK14 32/4885HSPB1 690/4885RAF1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.